II. Indications
- Hypertension
- Migraine Prophylaxis
- Atrial Fibrillation Rate Control
- Angina
- Esophageal Varices Prevention of Recurrent Bleeding
III. Mechanism
- Nonselective Beta Blocker (Beta-1 and Beta-2 Adrenergic Blockade)
IV. Dosing
- Dose: 40 mg orally daily
- Target: 40 to 80 mg/day
- Maximum 240 mg/day (Angina, Migraines, Atrial Fibrillation) to 320 mg/day (Hypertension)
- Renal Dysfunction
- Start 20 mg orally daily
- Decrease dosing frequency with Renal Insufficiency
- Creatinine Clearance 31 to 50 ml/min: Take every 24 to 36 hours
- Creatinine Clearance 10 to 30 ml/min: Take every 24 to 48 hours
- Creatinine Clearance <10 ml/min: Take every 40 to 60 hours
V. Adverse Effects
- See Beta Blocker
VI. Metabolism
- Not lipophilic
- Renal excretion
- Long Half life
VII. Safety
- Pregnancy Category C
- Avoid in Lactation
VIII. Resources
IX. References
- (2019) Presc Lett, Resource #350503, Comparison of Oral Beta Blockers
- (2020) Med Lett Drugs Ther 62(1598): 73-80
- Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 66-7
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
Images: Related links to external sites (from Bing)
Related Studies
nadolol (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
NADOLOL 20 MG TABLET | Generic | $0.19 each |
NADOLOL 40 MG TABLET | Generic | $0.32 each |
NADOLOL 80 MG TABLET | Generic | $0.50 each |
Ontology: Nadolol (C0027302)
Definition (NCI) | A non-selective beta-adrenergic antagonist with antihypertensive and antiarrhythmic activities. Nadolol competitively blocks beta-1 adrenergic receptors located in the heart and vascular smooth muscle, inhibiting the activities of the catecholamines epinephrine and norepinephrine and producing negative inotropic and chronotropic effects. This agent exhibits antiarrhythmic activity via the impairment of atrioventricular (AV) node conduction and a corresponding reduction in sinus rate. In the kidney, inhibition of the beta-2 receptor within the juxtaglomerular apparatus results in the inhibition of renin production and a subsequent reduction in angiotensin II and aldosterone levels, thus inhibiting angiotensin II-dependent vasoconstriction and aldosterone-dependent water retention. |
Definition (MSH) | A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D009248 |
SnomedCT | 387482003, 82896009 |
LNC | LP16211-2, MTHU003377 |
English | Nadolol, 2,3-Naphthalenediol, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-, nadolol, nadolol (medication), NADOLOL, Nadolol [Chemical/Ingredient], Nadolol (product), Nadolol (substance) |
Swedish | Nadolol |
Czech | nadolol |
Finnish | Nadololi |
Russian | NADOLOL, НАДОЛОЛ |
Japanese | ナドロール |
Polish | Nadolol |
Spanish | nadolol (producto), nadolol (sustancia), nadolol, Nadolol |
French | Nadolol |
German | Nadolol |
Italian | Nadololo |
Portuguese | Nadolol |
Ontology: Corgard (C0591292)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D009248 |
English | corgard, Corgard |